Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072091244> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2072091244 endingPage "765" @default.
- W2072091244 startingPage "762" @default.
- W2072091244 abstract "Many of the common problems in clinical practice today relate to thrombosis. The underlying final pathophysiological process in myocardial infarction and stroke is thrombus formation (thrombogenesis). Common cardiovascular disorders such as atrial fibrillation and heart failure are also associated with thrombogenesis. Thrombosis is also a clinical problem in various cancers and after surgery, especially orthopaedic.Routes to inhibiting platelet functionOver 150 years ago Virchow recognised three prerequisites for thrombogenesis: abnormal blood flow, vessel wall abnormalities, and blood constituent abnormalities. This concept has been extended by modern knowledge of the endothelial function, flow characteristics, and blood constituents including haemorheological factors, clotting factors, and platelet physiology. As thrombus consists of platelets and fibrin (and often bystanding erythrocytes) optimum antithrombotic prophylactic therapy can and should be directed towards both.### Aspirin and agents acting on the cyclo-oxygenase pathwayAspirin irreversibly inhibits cyclo-oxygenase by acetylation of amino acids that are next to the active site. In platelets, this is the rate limiting step in synthesis of thromboxane A2, and inhibition occurs in the megakaryocyte so that all budding platelets are dysfunctional. Because platelets are unable to regenerate fresh cyclo-oxygenase in response, the effect of aspirin remains as long as the lifespan of the platelet (generally about 10 days). A severe weakness of aspirin is that its specificity for cyclo-oxygenase means it has little effect on other pathways of platelet activation. Thus aspirin fails to prevent aggregation induced by thrombin and only partially inhibits that induced by ADP and high dose collagen. Antithrombotic doses used in clinical trials have varied widely from less than 50 mg to over 1200 mg/day, with no evidence of any difference in clinical efficacy. Absorption is over 80% with extensive presystemic metabolism to salicylic acid. Only the parent acetylsalicylic acid has any significant effect on platelet function.Key components of Virchow's triad (VWF=von Willebrand factor)View this table:Contraindications …" @default.
- W2072091244 created "2016-06-24" @default.
- W2072091244 creator A5069522757 @default.
- W2072091244 creator A5076002640 @default.
- W2072091244 creator A5088579117 @default.
- W2072091244 date "2002-10-05" @default.
- W2072091244 modified "2023-10-11" @default.
- W2072091244 title "An overview of antithrombotic therapy" @default.
- W2072091244 doi "https://doi.org/10.1136/bmj.325.7367.762" @default.
- W2072091244 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1124276" @default.
- W2072091244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12364307" @default.
- W2072091244 hasPublicationYear "2002" @default.
- W2072091244 type Work @default.
- W2072091244 sameAs 2072091244 @default.
- W2072091244 citedByCount "117" @default.
- W2072091244 countsByYear W20720912442012 @default.
- W2072091244 countsByYear W20720912442013 @default.
- W2072091244 countsByYear W20720912442014 @default.
- W2072091244 countsByYear W20720912442015 @default.
- W2072091244 countsByYear W20720912442016 @default.
- W2072091244 countsByYear W20720912442017 @default.
- W2072091244 countsByYear W20720912442018 @default.
- W2072091244 countsByYear W20720912442019 @default.
- W2072091244 countsByYear W20720912442020 @default.
- W2072091244 countsByYear W20720912442021 @default.
- W2072091244 countsByYear W20720912442022 @default.
- W2072091244 countsByYear W20720912442023 @default.
- W2072091244 crossrefType "journal-article" @default.
- W2072091244 hasAuthorship W2072091244A5069522757 @default.
- W2072091244 hasAuthorship W2072091244A5076002640 @default.
- W2072091244 hasAuthorship W2072091244A5088579117 @default.
- W2072091244 hasBestOaLocation W20720912442 @default.
- W2072091244 hasConcept C126322002 @default.
- W2072091244 hasConcept C177713679 @default.
- W2072091244 hasConcept C2522767166 @default.
- W2072091244 hasConcept C2777015399 @default.
- W2072091244 hasConcept C41008148 @default.
- W2072091244 hasConcept C71924100 @default.
- W2072091244 hasConceptScore W2072091244C126322002 @default.
- W2072091244 hasConceptScore W2072091244C177713679 @default.
- W2072091244 hasConceptScore W2072091244C2522767166 @default.
- W2072091244 hasConceptScore W2072091244C2777015399 @default.
- W2072091244 hasConceptScore W2072091244C41008148 @default.
- W2072091244 hasConceptScore W2072091244C71924100 @default.
- W2072091244 hasIssue "7367" @default.
- W2072091244 hasLocation W20720912441 @default.
- W2072091244 hasLocation W20720912442 @default.
- W2072091244 hasLocation W20720912443 @default.
- W2072091244 hasLocation W20720912444 @default.
- W2072091244 hasOpenAccess W2072091244 @default.
- W2072091244 hasPrimaryLocation W20720912441 @default.
- W2072091244 hasRelatedWork W1506200166 @default.
- W2072091244 hasRelatedWork W1995515455 @default.
- W2072091244 hasRelatedWork W2048182022 @default.
- W2072091244 hasRelatedWork W2080531066 @default.
- W2072091244 hasRelatedWork W2604872355 @default.
- W2072091244 hasRelatedWork W2748952813 @default.
- W2072091244 hasRelatedWork W2899084033 @default.
- W2072091244 hasRelatedWork W3031052312 @default.
- W2072091244 hasRelatedWork W3032375762 @default.
- W2072091244 hasRelatedWork W3108674512 @default.
- W2072091244 hasVolume "325" @default.
- W2072091244 isParatext "false" @default.
- W2072091244 isRetracted "false" @default.
- W2072091244 magId "2072091244" @default.
- W2072091244 workType "article" @default.